![]() |
市場調查報告書
商品編碼
1792304
近距離放射治療市場報告(按服務類型(病史和身體報告、出院總結、手術記錄或報告、諮詢報告等)、技術、採購模式、最終用戶和地區分類),2025 年至 2033 年Brachytherapy Market Report by Service Type (History and Physical Report, Discharge Summary, Operative Note or Report, Consultation Report, and Others ), Technology, Mode of Procurement, End-User, and Region 2025-2033 |
2024 年全球近距離放射治療市場規模達 8.881 億美元。展望未來, IMARC Group預計到 2033 年市場規模將達到 12.159 億美元,2025-2033 年期間的成長率 (CAGR) 為 3.55%。
近距離放射治療,也稱為體內放射治療,是一種放射治療形式,其放射線透過植入體內癌性腫瘤附近或旁邊的放射源直接傳輸。此放射源產生的伽馬射線聚焦於癌細胞,並減少對周圍健康組織的損傷。近距離放射治療依病情嚴重程度及其損傷程度,可採用低劑量率 (LDR) 或高劑量率 (HDR) 進行。 LDR 療法將微小的放射性粒子永久植入腫瘤內或周圍;而 HDR 療法則在每次治療結束時將放射源從患者體內移除,該療法用於高風險癌症病例。
各類癌症發生率的上升是推動全球市場發展的關鍵因素之一。近距離放射治療已被證明是治療子宮頸癌、皮膚癌和乳癌極為有效的方法,這顯著促進了該類市場的成長。此外,高品質的近距離放射治療設備能夠為小腫瘤提供精準且極其局部化的放射劑量,提高了患者和醫務人員對該療法的接受度。腫瘤治療技術的進步和廣泛的研發 (R&D),例如治療新生血管性老年黃斑部病變的試驗,也顯著促進了市場的成長。此外,全球醫療旅遊業的蓬勃發展,以及人們對近距離放射治療的優勢及其成本效益以及與手術或外照射治療 (EBT) 相比更高的治癒率的認知不斷提高,也顯著推動了市場的發展。
IMARC 集團的最新報告深入洞察了全球近距離放射治療市場,涵蓋了其所有重要方面。報告涵蓋了從宏觀市場概覽到微觀產業表現、近期趨勢、關鍵市場促進因素和挑戰、SWOT 分析、波特五力分析、價值鏈分析等內容。對於產業參與者、投資者、研究人員、顧問、商業策略家以及所有持有或計劃以任何方式進軍全球近距離放射治療市場的人士而言,本報告都是必讀之作。
The global brachytherapy market size reached USD 888.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,215.9 Million by 2033, exhibiting a growth rate (CAGR) of 3.55% during 2025-2033.
Brachytherapy, also known as internal radiation therapy, is a form of radiotherapy in which radiation is transported directly through a source implanted near or next to the cancerous tumor in the body. The source produces gamma rays that are focused on cancer cells and reduce the damage to surrounding healthy tissue. Brachytherapy is either administered in Low Dose Rate (LDR) or High Dose Rate (HDR) depending upon the severity of the disease and its damage. For LDR, small radioactive seeds are implanted permanently in or around the tumor, whereas, for HDR, radioactive sources are removed from the patient's body at the termination of each session and is used in the cases of high-risk cancers.
The rising prevalence of different types of cancer is one of the key factors driving the global market. Brachytherapy has been proven to be an extremely effective treatment option for cervical, skin and breast cancers, which is contributing significantly to its market growth. Furthermore, the availability of high-quality brachytherapy equipment that provides accurate and extremely localized doses of radiation to small tumors has enhanced the acceptance of the therapy amongst patients and medical professionals alike. Technological advancements in oncology treatments and extensive research and development (R&D), such as trials for treating neovascular age-related macular degeneration, have also provided a significant boost to the market growth. In addition to this, growing medical tourism across the globe, along with increasing awareness about the advantages of brachytherapy and its cost-effectiveness and increasing cure rate as compared to surgery or external beam therapy (EBT), is also significantly driving the market.
IMARC Group's latest report provides a deep insight into the global brachytherapy market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global brachytherapy market in any manner.
The report has also analyzed the competitive landscape of the market with some of the key players being Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus and Transtech Medical Solutions LLC.